Qiagen N.V. $QGEN Shares Bought by Natixis Advisors LLC

Natixis Advisors LLC grew its holdings in shares of Qiagen N.V. (NYSE:QGEN) by 7.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,411,746 shares of the company’s stock after purchasing an additional 103,049 shares during the quarter. Natixis Advisors LLC owned approximately 0.67% of Qiagen worth $63,486,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. United Services Automobile Association purchased a new position in shares of Qiagen during the 1st quarter worth $239,000. Prudential Financial Inc. raised its holdings in shares of Qiagen by 74.9% during the 2nd quarter. Prudential Financial Inc. now owns 8,873 shares of the company’s stock worth $426,000 after acquiring an additional 3,799 shares during the period. Invesco Ltd. raised its holdings in shares of Qiagen by 123.7% during the 2nd quarter. Invesco Ltd. now owns 1,006,025 shares of the company’s stock worth $48,350,000 after acquiring an additional 556,387 shares during the period. EverSource Wealth Advisors LLC raised its holdings in shares of Qiagen by 226.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company’s stock worth $125,000 after acquiring an additional 1,802 shares during the period. Finally, First Trust Advisors LP purchased a new position in shares of Qiagen during the 2nd quarter worth $3,639,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Wall Street Analysts Forecast Growth

QGEN has been the topic of several analyst reports. Zacks Research upgraded Qiagen from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 29th. JPMorgan Chase & Co. reduced their price target on Qiagen from $60.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, April 29th. Citigroup reiterated a “hold” rating on shares of Qiagen in a report on Monday, May 18th. UBS Group set a $52.00 price target on Qiagen in a report on Monday, February 9th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $43.00 price target on shares of Qiagen in a report on Thursday, April 30th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $44.98.

Qiagen Stock Down 1.3%

Shares of QGEN opened at $35.72 on Wednesday. The firm has a market cap of $7.36 billion, a P/E ratio of 18.65, a price-to-earnings-growth ratio of 3.60 and a beta of 0.66. Qiagen N.V. has a 12-month low of $32.53 and a 12-month high of $57.81. The company’s 50-day moving average price is $37.60 and its 200 day moving average price is $44.67. The company has a current ratio of 3.21, a quick ratio of 2.57 and a debt-to-equity ratio of 0.49.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.54 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.54. The firm had revenue of $492.32 million for the quarter, compared to analyst estimates of $496.15 million. Qiagen had a net margin of 19.16% and a return on equity of 14.40%. During the same period in the previous year, the firm earned $0.56 EPS. On average, sell-side analysts forecast that Qiagen N.V. will post 2.43 earnings per share for the current year.

Qiagen Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Tuesday, July 14th. Investors of record on Tuesday, July 7th will be issued a $0.35 dividend. This is an increase from Qiagen’s previous annual dividend of $0.26. The ex-dividend date is Tuesday, July 7th. This represents a yield of 104.0%. Qiagen’s payout ratio is presently 13.61%.

Qiagen Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.